Opdivo (Nivolumab) vs Tazverik (tazemetostat)

Opdivo (nivolumab) is an immune checkpoint inhibitor that works by blocking the PD-1 pathway, which can help the immune system recognize and attack cancer cells, and is commonly used in the treatment of various types of cancers, including melanoma, lung cancer, and kidney cancer. Tazverik (tazemetostat) is an EZH2 inhibitor that works by targeting the enzyme EZH2, potentially blocking a mechanism cancer cells can use to evade the immune system, and is specifically approved for the treatment of epithelioid sarcoma and certain types of non-Hodgkin's lymphoma. When deciding between these medications, it is crucial to consider the specific type of cancer being treated, as each drug is approved for different indications and their effectiveness can vary greatly depending on the cancer's genetic profile and stage.

Difference between Opdivo and Tazverik

Metric	Opdivo (Nivolumab)	Tazverik (tazemetostat)
Generic name	Nivolumab	Tazemetostat
Indications	Various types of cancer including melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancer, and others.	Epithelioid sarcoma, follicular lymphoma
Mechanism of action	Programmed death receptor-1 (PD-1) blocking antibody, which helps to restore the immune system’s ability to fight cancer.	Inhibitor of the EZH2 methyltransferase, which may help in treating cancers that are associated with an aberrant EZH2 gene.
Brand names	Opdivo	Tazverik
Administrative route	Intravenous infusion	Oral
Side effects	Fatigue, rash, musculoskeletal pain, pruritus, diarrhea, nausea, weakness, upper respiratory tract infection, cough, difficulty breathing, decreased appetite, etc.	Fatigue, musculoskeletal pain, nausea, abdominal pain, dyspnea, cough, decreased appetite, vomiting, constipation, etc.
Contraindications	Known hypersensitivity to nivolumab or any of its excipients.	Known hypersensitivity to tazemetostat or any of its excipients.
Drug class	Immune checkpoint inhibitor	EZH2 inhibitor
Manufacturer	Bristol-Myers Squibb	Epizyme, Inc.

Efficacy

Efficacy of Opdivo (Nivolumab) in Lymphoma

Opdivo (Nivolumab) is a PD-1 (Programmed Death-1) immune checkpoint inhibitor that has shown efficacy in the treatment of certain types of lymphoma. It is particularly effective in Hodgkin lymphoma, especially after other treatments have failed. Clinical trials have demonstrated that Nivolumab can induce a response in a significant proportion of patients with relapsed or refractory classical Hodgkin lymphoma. The drug works by blocking the PD-1 pathway, which cancer cells often exploit to evade the immune system. By inhibiting this pathway, Opdivo helps to restore the immune system's ability to detect and fight cancer cells.

In non-Hodgkin lymphoma, the efficacy of Opdivo has been studied in various subtypes. While the response rates may vary depending on the specific type of lymphoma, Opdivo has shown promise in certain forms such as diffuse large B-cell lymphoma (DLBCL) when combined with other therapies. It is important to note that the efficacy can be influenced by factors such as the patient's prior treatments and the stage of the disease.

Efficacy of Tazverik (Tazemetostat) in Lymphoma

Tazverik (Tazemetostat) is an EZH2 inhibitor used in the treatment of certain types of lymphoma. It has been approved for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Additionally, Tazverik has shown efficacy in the treatment of relapsed or refractory follicular lymphoma in patients who have received at least two prior systemic therapies. This drug works by inhibiting the activity of the EZH2 enzyme, which can play a role in the growth of cancer cells.

The efficacy of Tazverik in follicular lymphoma has been demonstrated in clinical trials, where it achieved objective response rates in a proportion of patients. The duration of response has also been a point of interest, with some patients experiencing a sustained response to the treatment. As with other therapies, the efficacy of Tazverik can vary based on individual patient characteristics and the biology of the tumor. It is also being investigated for use in other types of non-Hodgkin lymphoma, with ongoing studies to better understand its full potential and efficacy in these settings.

Regulatory Agency Approvals

Opdivo

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Therapeutic Goods Administration (TGA), Australia
Medsafe (NZ)

Tazverik

Food and Drug Administration (FDA), USA
Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Access Opdivo or Tazverik today

If Opdivo or Tazverik are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Opdivo

Buy Tazverik

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: